Significant differences were found in 3-year overall survival ( Combined Therapy , 23.08 % ; Monotherapy , 14.81 % ; P = 0.0473 ) and liver metastases-free survival ( Combined Therapy , 80.77 % ; Monotherapy , 55.56 % ; P = 0.0014 ) .